Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lazanda, Fentanyl
Fentanyl pectin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Fentanyl pectin | DRUG | comparison of Intranasal fentanyl 100mcg vs 200 mcg. |
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
Fentanyl pectin is being studied for the management of acute pain, including pain associated with cystoscopic procedures. It is an investigational formulation in clinical development and is not approved for any indication.
Fentanyl pectin works as an agonist at the mu-opioid receptor, also known as OPRM1. By activating this receptor, it produces analgesic effects. The pectin component is part of the formulation, but the pharmacological action is mediated through OPRM1 agonism.
Fentanyl pectin is being developed by Assertio Holdings, Inc., which trades under the ticker ASRT. The company is responsible for the clinical development of this investigational product.
Fentanyl pectin is in Phase 1 clinical development. It has not been approved by the FDA and remains an investigational therapy. The Phase 1 program includes one completed trial.
Fentanyl pectin has been evaluated in one completed Phase 1 trial, NCT01756651, titled Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures. The trial enrolled 20 male participants aged 18 years and older in the United States.